JP2023518443A5 - - Google Patents

Info

Publication number
JP2023518443A5
JP2023518443A5 JP2022556175A JP2022556175A JP2023518443A5 JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5 JP 2022556175 A JP2022556175 A JP 2022556175A JP 2022556175 A JP2022556175 A JP 2022556175A JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5
Authority
JP
Japan
Prior art keywords
mutant protein
sequence
protein according
mutant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022556175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518443A (ja
JP7882781B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/081841 external-priority patent/WO2021185362A1/zh
Publication of JP2023518443A publication Critical patent/JP2023518443A/ja
Publication of JP2023518443A5 publication Critical patent/JP2023518443A5/ja
Application granted granted Critical
Publication of JP7882781B2 publication Critical patent/JP7882781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022556175A 2020-03-19 2021-03-19 インターロイキン2変異体およびその使用 Active JP7882781B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010196689 2020-03-19
CN202010196689.5 2020-03-19
PCT/CN2021/081841 WO2021185362A1 (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Publications (3)

Publication Number Publication Date
JP2023518443A JP2023518443A (ja) 2023-05-01
JP2023518443A5 true JP2023518443A5 (cg-RX-API-DMAC7.html) 2024-04-02
JP7882781B2 JP7882781B2 (ja) 2026-06-30

Family

ID=77768025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556175A Active JP7882781B2 (ja) 2020-03-19 2021-03-19 インターロイキン2変異体およびその使用

Country Status (9)

Country Link
US (1) US20230174604A1 (cg-RX-API-DMAC7.html)
EP (1) EP4122951A4 (cg-RX-API-DMAC7.html)
JP (1) JP7882781B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220155317A (cg-RX-API-DMAC7.html)
CN (2) CN115315437B (cg-RX-API-DMAC7.html)
AU (1) AU2021237518B2 (cg-RX-API-DMAC7.html)
CA (1) CA3175728A1 (cg-RX-API-DMAC7.html)
TW (1) TWI834031B (cg-RX-API-DMAC7.html)
WO (1) WO2021185362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質
WO2023131270A1 (en) * 2022-01-07 2023-07-13 Cure Genetics, Co., Limited Novel interleukin-2 polypeptides
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR102629162B1 (ko) 2022-11-04 2024-01-29 한국기초과학지원연구원 바이오의약품 품질관리를 위한 잔류 숙주세포 단백질 정량 분석 방법 및 시스템
WO2024146575A1 (zh) * 2023-01-04 2024-07-11 北京晶泰科技有限公司 白细胞介素-2变体及其应用
KR20260008731A (ko) * 2023-03-21 2026-01-16 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-pd-1 및 돌연변이 il-2 면역접합체 제제
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6960652B2 (en) * 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN104231068A (zh) * 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
CN112105634B (zh) * 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
TWI825544B (zh) * 2020-12-31 2023-12-11 大陸商信達生物製藥(蘇州)有限公司 含異二聚體抗體Fc的蛋白以及其製備方法

Similar Documents

Publication Publication Date Title
TWI790573B (zh) 白介素2突變體及其用途
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
JP7765181B2 (ja) 改変されたil-2 fc融合タンパク質
JP2023518434A5 (cg-RX-API-DMAC7.html)
AU2017201056B2 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
CN112105634A (zh) 新型白介素2及其用途
JP5077924B2 (ja) 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物
EP4122951A1 (en) Interleukin-2 mutant and use thereof
KR20190129896A (ko) Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
KR20170017846A (ko) Sirp-알파 변이체 구성체 및 이의 용도
CN107636014A (zh) 抗癌融合多肽
JPH09508009A (ja) Fas抗原を結合するリガンド
WO2000017350A1 (fr) Sequence codante pour un nouveau facteur de differenciation de la croissance d'origine humaine et polypeptide code par cette sequence d'adn, et methode de production correspondante
CN111892661A (zh) 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用
WO2022226054A2 (en) Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
CN117586344A (zh) 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
JP2005535353A (ja) C4bpスカフォールドを使用した、多量体融合タンパク質の産生
US20040009950A1 (en) Secreted human proteins
CN112480237B (zh) 一种融合蛋白及其制备方法和应用
CN113912735B (zh) 多肽二聚体及其用途
JPH0380096A (ja) モチリン様ポリペプチドの製法並びにそのための組換えdna及び発現用プラスミド
US7462704B2 (en) Tumor marker and its use
US20070275419A1 (en) Tumor tag and the use thereof
WO2022007885A1 (zh) 融合多肽和多肽二聚体及其用途
WO2026036390A1 (zh) 白介素12突变体及其用途